Shukra Pharmaceuticals Ltd
SHUKRAPHARShukra Pharmaceuticals Ltd
SHUKRAPHAR
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 28.06 | 7.01 | 0.27% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Shukra Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceuticals Products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5.01 | 5.21 | 5.48 | 5.70 | 11.95 | 11.56 | 20.57 | 60.03 | 77.39 | 42.18 | ||||||||||
Raw Materials | 1.64 | 0.95 | 0.89 | 1.16 | 3.33 | 2.96 | 11.08 | 45.65 | 43.78 | 23.06 | ||||||||||
| Power & Fuel Cost | 0.26 | 0.26 | 0.29 | 0.34 | 1.64 | 1.78 | 0.00 | 0.00 | 0.00 | |||||||||||
| Employee Cost | 1.13 | 1.05 | 1.23 | 1.91 | 4.34 | 3.75 | 4.57 | 4.41 | 5.02 | |||||||||||
| Selling & Administrative Expenses | 0.44 | 0.92 | 1.20 | 0.71 | 1.21 | 1.36 | 2.44 | 3.38 | 5.15 | |||||||||||
| Operating & Other expenses | 0.75 | 0.49 | 0.15 | -0.11 | -0.21 | 0.10 | -0.49 | 0.03 | 1.21 | |||||||||||
EBITDA | 0.79 | 1.54 | 1.72 | 1.69 | 1.64 | 1.61 | 2.97 | 6.56 | 22.23 | 19.12 | ||||||||||
| Depreciation/Amortization | 0.45 | 0.47 | 0.74 | 0.96 | 1.48 | 1.47 | 1.66 | 1.84 | 2.05 | 2.40 | ||||||||||
| PBIT | 0.34 | 1.07 | 0.98 | 0.73 | 0.16 | 0.14 | 1.31 | 4.72 | 20.18 | 16.72 | ||||||||||
| Interest & Other Items | 0.00 | 0.01 | 0.04 | 0.00 | 0.00 | 0.03 | 0.29 | 0.28 | 0.29 | 0.31 | ||||||||||
| PBT | 0.34 | 1.06 | 0.94 | 0.73 | 0.16 | 0.11 | 1.02 | 4.44 | 19.89 | 16.41 | ||||||||||
| Taxes & Other Items | 0.23 | 0.55 | 0.42 | 0.27 | 0.14 | -0.09 | 0.27 | 0.04 | 1.34 | 2.00 | ||||||||||
| Net Income | 0.11 | 0.51 | 0.52 | 0.46 | 0.02 | 0.20 | 0.75 | 4.40 | 18.55 | 14.41 | ||||||||||
| EPS | 0.04 | 0.17 | 0.17 | 0.15 | 0.01 | 0.07 | 0.25 | 2.42 | 7.40 | 3.29 | ||||||||||
| DPS | 0.00 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.03 | 0.13 | 0.25 | 1.00 | ||||||||||
| Payout ratio | 0.00 | 0.15 | 0.15 | 0.17 | 0.00 | 0.00 | 0.10 | 0.05 | 0.03 | 0.30 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Shukra Pharmaceuticals Ltd | 21.79 | 7.01 | 0.27% |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare SHUKRAPHAR with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateAug 31, 2018
Dividend/Share
₹0.50
Ex DateEx Date
Aug 31, 2018
Net profit of Shukra Pharmaceuticals declined 88.54% to Rs 0.54 crore in the quarter ended September 2024 as against Rs 4.71 crore during the previous quarter ended September 2023. Sales declined 77.44% to Rs 5.56 crore in the quarter ended September 2024 as against Rs 24.64 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5.5624.64 -77 OPM %12.0520.62 - PBDT1.585.26 -70 PBT0.884.70 -81 NP0.544.71 -89 Powered by Capital Market - Live
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 September 2024.Powered by Capital Market - Live
Shukra Pharmaceuticals announced that the 31th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net profit of Shukra Pharmaceuticals rose 16.67% to Rs 0.49 crore in the quarter ended June 2024 as against Rs 0.42 crore during the previous quarter ended June 2023. Sales declined 84.23% to Rs 3.18 crore in the quarter ended June 2024 as against Rs 20.16 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3.1820.16 -84 OPM %25.791.69 - PBDT1.480.89 66 PBT0.810.43 88 NP0.490.42 17 Powered by Capital Market - Live
Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Shukra Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 23 August 2024 .Powered by Capital Market - Live
Crorepati stocks! How these 12 tiny stocks turned Rs 1 lakh to up to Rs 2 crore
Given multibagger return YTD, this pharma stock fixes record date for dividend
Shukra Pharmaceuticals board approves rights issue worth Rs19 crore; Stock climbs 3.4%
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 68.49%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 0.02%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 109.47%, vs industry avg of 15.27%